Update on retinopathy of prematurity: Treatment options and outcomes

Current Opinion in Ophthalmology

Volumn 21, Issue 5, 2010, Pages 329-334

  Salvin, Jonathan H ^a,b   Lehman, Sharon S ^a,b   Jin, Jing ^a,b   Hendricks, Dorothy H ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

laser photocoagulation; retinopathy of prematurity; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; RECOMBINANT ERYTHROPOIETIN; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN;

AMBLYOPIA; ANGIOGENESIS; ANISOMETROPIA; ASTIGMATISM; CATARACT; CATARACTOGENESIS; CLOSED ANGLE GLAUCOMA; CORNEA EDEMA; CRYOTHERAPY; DIODE LASER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE EXAMINATION; FOLLOW UP; HUMAN; INTRAOCULAR HEMORRHAGE; LASER COAGULATION; LONG TERM CARE; MYOPIA; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA SURGERY; RETROLENTAL FIBROPLASIA; REVIEW; RISK ASSESSMENT; STRABISMUS; TREATMENT OUTCOME; UPREGULATION; VITRECTOMY; CLASSIFICATION; NEWBORN; RETINOPATHY OF PREMATURITY;

HUMANS; INFANT, NEWBORN; PRACTICE GUIDELINES AS TOPIC; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME;

EID: 77955924199     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833cd40b     Document Type: Review

References (35)

1. Haddad MA, Sei M, Sampaio MW, et al. Causes of visual impairment in children: a study of 3,210 cases. J Pediatric Ophthalmol Strabismus 2007; 44:232-240.
2. Centers for Disease Control and Prevention. Birth data. http://www.cdc.gov/ nchs/births.htm. [Accessed 12 March 2010]
3. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 2005; 123:991-999.
4. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 1988; 106:471-479.
5. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 2003; 121:1684-1696.
6. Section on Ophthalmology, American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117:572-576.
7. Soh Y, Fujino T, Hatsukawa Y. Progression and timing of treatment of zone I retinopathy of prematurity. Am J Ophthalmol 2008; 146:369-374.
8. Palmer E. The factor of time in retinopathy of prematurity. J AAPOS 2006; 10:500-506.
9. Palmer EA, Hardy RJ, Dobson V. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005; 123:311-318.
10. Ng EY, Connolly BP, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years. Part 1: Visual function and structural outcome. Ophthalmology 2002; 109:928-935.
11. Connolly BP, Ng EY, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years. Part 2: Refractive outcome. Ophthalmology 2002; 109:936-941.
12. Axer-Siegel R, Maharshak I, Snir M, et al. Diode laser treatment of retinopathy of prematurity: anatomic and refractive outcomes. Retina 2008; 28:839-846.
13. Parvaresh MM, Modarres M, Falavarjani KG, et al. Transscleral diode laser retinal photocoagulation for the treatment of threshold retinopathy of prematurity. J AAPOS 2009; 13:535-538.
14. Trigler L, Weaver RG, O'Neil J, et al. Case Series of angle-closure glaucoma after laser treatment for retinopathy of prematurity. J AAPOS 2005; 9:17-21.
15. Sonmez K, Drenser KA, Capone A, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115:1065-1070.
16. Sato T, Kusaka S, Shimojo H, Fukikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009; 116:2165-2169.
17. Andreoli CM, Miller JW. Antivascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18:502-508.
18. Kong L, Mintz-Hittner HA, et al. Intravitreous Bevacizumab as antivascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008; 126:1161-1163.
19. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009; 29:579-585.
20. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009; 148:536-543.
21. Darlow BA, Gilbert C, Quinn GE, et al. Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity. Br J Ophthalmol 2009; 93:986.
22. Mintz-Hittner H. BEAT-ROP study. http://www.clinicaltrials.gov. [Accessed 19 March 2010]
23. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64:326-333.
24. Suk KK, Dunbar JA, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008; 12:233-238.
25. Shah N, Jadav P, et al. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 2010; 27:67-71.
26. McLoone E, O'Keefe M, Lanigan B. Effect of diode laser ablative therapy for threshold retinopathy of prematurity on the visual field: results of Goldmann perimetry at a mean age of 11 years. J Pediatr Ophthalmol Strabismus 2007; 44:170-173.
27. Hamilton R, Bradnam MS, Dudgeon J, Mactier H. Maturation of rod function in preterm infants with and without retinopathy of prematurity. J Pediatr 2008; 153:605-611.
28. Vanderveen DK, Coats DK, Dobson V, et al. Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity. Arch Ophthalmol 2006; 124:766-773.
29. Quinn GE, Dobson V, Davitt BV, et al. Progression of myopia and high myopia in early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008; 115:1058-1064.
30. Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity. Am J Ophthalmol 2008; 145:1090-1094.
31. Davitt BV, Dobson V, Quinn GE, et al. Astigmatism in the early treatment for retinopathy of prematurity study. Ophthalmology 2009; 116:332-339.
32. Holmstrom G, Larsson E. Long-term follow-up of visual functions in prematurely born children: a prospective population-based study up to 10 years of age. J AAPOS 2008; 12:157-162.
33. Smith BT, Tasman WS. Retinopathy of prematurity: late complications in the baby boomer generation (1946-1964). Trans Am Ophthalmol Soc 2005; 103:225-236.
34. Kaiser RS, Fenton GL, Tasman W, Trese MT. Adult retinopathy of prematurity: retinal complications from cataract surgery. Am J Ophthalmol 2008; 145:729-735.
35. Dunbar J, Hsu V, Christensen M, et al. Cost-utility analysis of screening and laser treatment of retinopathy of prematurity. J AAPOS 2009; 13:186-190.